Arcturus Therapeutics Holdings (ARCT) Tax Provisions (2022 - 2025)
Arcturus Therapeutics Holdings' (ARCT) quarterly Tax Provisions came in at -$17814.0 in Q4 2025, down 345.35% YoY from $7260.6 in Q4 2024, and down 545.35% on a QoQ basis from $4000.0 in Q2 2025.
Powered by 
Analysis
Arcturus Therapeutics Holdings (ARCT) Tax Provisions (2022 - 2025) Analysis & Trends
Arcturus Therapeutics Holdings (ARCT) has 4 years of Tax Provisions data on file, last reported at -$17814.0 in Q4 2025.
- Quarterly Tax Provisions fell 345.35% year-over-year to -$17814.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$13814.0 (up 73.94% YoY) and the FY2025 annual result came in at -$13814.0, down 245.35% from the prior year.
- Tax Provisions slipped to -$17814.0 in Q4 2025, from $4000.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $900000.0 in Q3 2023 to a low of -$217000.0 in Q3 2024.
- A 4-year average of $172562.4 and a median of $100000.0 in 2022 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2024 — Tax Provisions surged 257.28% — and 2025, when it plunged 345.35%.
- Tracing ARCT's Tax Provisions over 4 years: stood at $100000.0 in 2022, then soared by 162.0% to $262000.0 in 2023, then plunged by 101.53% to -$4000.0 in 2024, then sank by 345.35% to -$17814.0 in 2025.
- The last three Tax Provisions figures came in at -$17814.0 (Q4 2025), $4000.0 (Q2 2025), and -$4000.0 (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Arcturus Therapeutics Holdings | 449.65 Mn | 258.17 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -17,814.00 |
| Jun 30, 2025 | 4,000.00 |
| Dec 31, 2024 | -4,000.00 |
| Sep 30, 2024 | -217,000.00 |
| Jun 30, 2024 | -200,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Dec 31, 2023 | 235,000.00 |
| Sep 30, 2023 | 900,000.00 |
| Jun 30, 2023 | 600,000.00 |
| Mar 31, 2023 | 103,000.00 |
| Mar 31, 2022 | 100,000.00 |